Literature DB >> 21494409

Efficacy of Vitamin E Treatment for Hand-Foot Syndrome in Patients Receiving Capecitabine.

Daigo Yamamoto1, Chizuko Yamamoto, Satoru Iwase, Yujiro Kuroda, Hiroki Odagiri, Yoshinori Nagumo.   

Abstract

Entities:  

Year:  2010        PMID： 21494409      PMCID： PMC3076356          DOI： 10.1159/000322660

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  15 in total

1.  Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.

Authors:  Ismail Oguz Kara; Berksoy Sahin; M Erkisi
Journal:  Breast       Date:  2005-09-26       Impact factor: 4.380

Review 2.  Management of hand-foot syndrome induced by capecitabine.

Authors:  Sarah M Gressett; Brad L Stanford; Fred Hardwicke
Journal:  J Oncol Pharm Pract       Date:  2006-09       Impact factor: 1.809

3.  Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.

Authors:  J L Blum; V Dieras; P M Lo Russo; J Horton; O Rutman; A Buzdar; B Osterwalder
Journal:  Cancer       Date:  2001-10-01       Impact factor: 6.860

4.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Authors:  Kathy D Miller; Linnea I Chap; Frankie A Holmes; Melody A Cobleigh; P Kelly Marcom; Louis Fehrenbacher; Maura Dickler; Beth A Overmoyer; James D Reimann; Amy P Sing; Virginia Langmuir; Hope S Rugo
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

5.  Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors.

Authors:  M M Asgari; J G Haggerty; J M McNiff; L M Milstone; P M Schwartz
Journal:  J Cutan Pathol       Date:  1999-07       Impact factor: 1.587

6.  Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.

Authors:  M Miwa; M Ura; M Nishida; N Sawada; T Ishikawa; K Mori; N Shimma; I Umeda; H Ishitsuka
Journal:  Eur J Cancer       Date:  1998-07       Impact factor: 9.162

7.  Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.

Authors:  P Reichardt; G Von Minckwitz; P C Thuss-Patience; W Jonat; H Kölbl; F Jänicke; D G Kieback; W Kuhn; A E Schindler; S Mohrmann; M Kaufmann; H J Lück
Journal:  Ann Oncol       Date:  2003-08       Impact factor: 32.976

8.  Potential regional differences for the tolerability profiles of fluoropyrimidines.

Authors:  Daniel G Haller; Jim Cassidy; Stephen J Clarke; David Cunningham; Eric Van Cutsem; Paulo M Hoff; Mace L Rothenberg; Leonard B Saltz; Hans-Joachim Schmoll; Carmen Allegra; Joseph R Bertino; Jean-Yves Douillard; Bengt G Gustavsson; Gerard Milano; Michael O'Connell; Youcef Rustum; Josep Tabernero; Frank Gilberg; Florin Sirzén; Chris Twelves
Journal:  J Clin Oncol       Date:  2008-05-01       Impact factor: 44.544

Review 9.  Capecitabine-based combination therapy for breast cancer: implications for nurses.

Authors:  Debra K Frye
Journal:  Oncol Nurs Forum       Date:  2009-01       Impact factor: 2.172

10.  A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.

Authors:  Daigo Yamamoto; Satoru Iwase; Kaoru Kitamura; Hiroki Odagiri; Chizuko Yamamoto; Yoshinori Nagumo
Journal:  Cancer Chemother Pharmacol       Date:  2007-05-22       Impact factor: 3.333
View more
  3 in total

1.  Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.

Authors:  Rena C Zuo; Andrea B Apolo; John J DiGiovanna; Howard L Parnes; Corrine M Keen; Swati Nanda; William L Dahut; Edward W Cowen
Journal:  JAMA Dermatol       Date:  2015-02       Impact factor: 10.282

2.  Prevention of palmoplantar erythrodysesthesia in patients treated with pegylated liposomal doxorubicin (Caelyx®).

Authors:  S Jung; J Sehouli; R Chekerov; F Kluschke; A Patzelt; H Fuss; F Knorr; J Lademann
Journal:  Support Care Cancer       Date:  2017-06-26       Impact factor: 3.603

Review 3.  Carotenoids in Human SkinIn Vivo: Antioxidant and Photo-Protectant Role against External and Internal Stressors.

Authors:  Maxim E Darvin; Jürgen Lademann; Jörg von Hagen; Silke B Lohan; Harald Kolmar; Martina C Meinke; Sora Jung
Journal:  Antioxidants (Basel)       Date:  2022-07-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.